Literature DB >> 11160964

Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis.

F Villani1, R Spreafico, L Farina, A R Giovagnoli, P Bernasconi, T Granata, G Avanzini.   

Abstract

Rasmussen's encephalitis (RE) is a rare and progressive neurologic condition of uncertain etiology that typically has a childhood onset. The authors describe a 45-year-old woman with adult-onset progressive aphasia, right hemiparesis, severe drug refractory epilepsy, and left cerebral hemisphere atrophy. High-dose corticosteroids and plasmapheresis were not effective. She improved with high-dose therapy with human IV immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160964     DOI: 10.1212/wnl.56.2.248

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 2.  Hemispherectomy in the treatment of seizures: a review.

Authors:  Sean M Lew
Journal:  Transl Pediatr       Date:  2014-07

3.  Epilepsy surgery in adult-onset Rasmussen's encephalitis: case series and review of the literature.

Authors:  Sara Casciato; Carlo Di Bonaventura; Anna Teresa Giallonardo; Jinane Fattouch; Pier Paolo Quarato; Addolorata Mascia; Alfredo D'Aniello; Andrea Romigi; Vincenzo Esposito; Giancarlo Di Gennaro
Journal:  Neurosurg Rev       Date:  2015-04-16       Impact factor: 3.042

4.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

Review 5.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

6.  Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?

Authors:  L Chiapparini; T Granata; L Farina; E Ciceri; A Erbetta; F Ragona; E Freri; L Fusco; G Gobbi; G Capovilla; L Tassi; L Giordano; M Viri; B Dalla Bernardina; R Spreafico; M Savoiardo
Journal:  Neuroradiology       Date:  2003-02-12       Impact factor: 2.804

Review 7.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Authors:  Sophia Varadkar; Christian G Bien; Carol A Kruse; Frances E Jensen; Jan Bauer; Carlos A Pardo; Angela Vincent; Gary W Mathern; J Helen Cross
Journal:  Lancet Neurol       Date:  2014-02       Impact factor: 44.182

Review 8.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 9.  Encephalitis and epilepsy.

Authors:  Jan Bauer; Christian G Bien
Journal:  Semin Immunopathol       Date:  2009-09-11       Impact factor: 9.623

Review 10.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.